StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma r&d expenses

Research and development expenses are spending on new products and technology.

Lyell Immunopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $156.50M, down 6.0% year over year. For fiscal 2025 it was $158.68M, down 7.5% from the year before. The highest annual figure on record is $182.95M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$158.68M-7.5%
FY2024Dec 31, 2024$171.60M-6.2%
FY2023Dec 31, 2023$182.95M+14.9%
FY2022Dec 31, 2022$159.19M+14.8%
FY2021Dec 31, 2021$138.69M-23.9%
FY2020Dec 31, 2020$182.24M+186.6%
FY2019Dec 31, 2019$63.60M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$39.52M+13.4%
Q1 FY2026Mar 31, 2026$36.60M-15.8%
Q4 FY2025Dec 31, 2025$52.20M+7.3%
Q3 FY2025Sep 30, 2025$28.17M-28.7%
Q2 FY2025Jun 30, 2025$34.86M-13.4%
Q1 FY2025Mar 31, 2025$43.45M+0.6%
Q4 FY2024Dec 31, 2024$48.67M+3.6%
Q3 FY2024Sep 30, 2024$39.50M-9.9%
Q2 FY2024Jun 30, 2024$40.26M-15.2%
Q1 FY2024Mar 31, 2024$43.17M-3.3%
Q4 FY2023Dec 31, 2023$47.00M+23.6%
Q3 FY2023Sep 30, 2023$43.85M+5.4%
Q2 FY2023Jun 30, 2023$47.47M+8.6%
Q1 FY2023Mar 31, 2023$44.63M+24.6%
Q4 FY2022Dec 31, 2022$38.03M+97.2%
Q3 FY2022Sep 30, 2022$41.61M+32.4%
Q2 FY2022Jun 30, 2022$43.72M-5.9%
Q1 FY2022Mar 31, 2022$35.83M-13.7%
Q4 FY2021Dec 31, 2021$19.29M-45.0%
Q3 FY2021Sep 30, 2021$31.43M+28.3%
Q2 FY2021Jun 30, 2021$46.45M-52.2%
Q1 FY2021Mar 31, 2021$41.53M–
Q4 FY2020Dec 31, 2020$35.09M–
Q3 FY2020Sep 30, 2020$24.50M–
Q2 FY2020Jun 30, 2020$97.15M–

More Lyell Immunopharma figures

See a number that looks wrong?